Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about XLO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Vilastobart | Advanced Solid Tumor | Phase 1/2 · NCT04896697 | Completed |
| Protein-engineered Interleukin-2 XTX202 | Advanced Solid Tumor | Phase 1/2 · NCT05052268 | Completed |
| Protein-engineered Interleukin-12 XTX301 | Advanced Solid Tumor | Phase 1/2 · NCT05684965 | Recruiting |
Also used in these trials (approved or third-party drugs, not XLO's own candidates): Atezolizumab, Retifanlimab, Tumor Protease-activated Anti-PD-1/IL-2 Fusion Protein XTX501.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
XLO holds $122.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.3M/quarter from operations, an estimated runway of 22.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 28 · Moderate
Based on our current operating plans, we anticipate that our existing cash and cash equivalents as of September 30, 2026 will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XLO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 5%+ holder (13G) | 14,517,678 | 205.52% | 2025-12-31 |
| Frazier Life Sciences Public Fund, L.P. | 5%+ holder (13G) | 4,676,472 | 66.20% | 2025-12-31 |
| Sirenia Capital Management LP | Institution (13G, 5%+) | 1,142,862 | 16.18% | 2026-03-31 |
| Coastlands Capital LP | Institution (13G, 5%+) | 731,573 | 10.36% | 2026-09-30 |
| BCLS II Equity Opportunities, LP | 5%+ holder (13G) | 664,021 | 9.40% | 2026-03-31 |
| ORBIMED ADVISORS LLC | Institution (13G, 5%+) | 642,000 | 9.09% | 2026-03-31 |
| StemPoint Capital LP | Institution (13G, 5%+) | 628,866 | 8.90% | 2026-06-30 |
| Adage Capital Management, L.P. | Institution (13G, 5%+) | 464,598 | 6.58% | 2026-09-30 |
| Rene Russo PRESIDENT AND CEO, Director · +3.98M options |
Insider | 325,422 | 4.61% | 2025-12-31 |
| Katarina Luptakova CHIEF MEDICAL OFFICER · +910,345 options |
Insider | 33,250 | 0.47% | 2025-12-31 |
| Christopher James Frankenfield Chief Financial Officer · +1.88M options |
Insider | 24,766 | 0.35% | 2025-12-31 |
| James Samuel Shannon Director · +36,000 options |
Insider | 10,000 | 0.14% | 2026-03-26 |
Share count 7,063,982 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XLO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →